ISR IsoRay

Isoray To Announce Fourth Quarter and Fiscal Year End 2020 Financial Results on September 17, 2020

Isoray To Announce Fourth Quarter and Fiscal Year End 2020 Financial Results on September 17, 2020

Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT

RICHLAND, Wash., Sept. 10, 2020 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2020 on Thursday, September 17, 2020, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2020 after the close of the U.S. stock markets on September 17, 2020. 

To listen to the conference call, please dial (844) 602-0380. For callers outside the U.S., please dial (862) 298-0970.

The conference call will be simultaneously webcast and can be accessed at  by clicking on the link. The webcast will be available until September 17, 2021 following the conference call.

About Isoray

Isoray, Inc., through its subsidiary, Isoray Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131, commercially known as Cesium Blu, by visiting . Follow us on and . Join us on .

Contact
Investor Relations: Mark Levin (501) 255-1910
Media and Public Relations: Sharon Schultz (302) 539-3747
EN
10/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IsoRay

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Perspective Therapeutics Presents at the Society of Nuclear Medicine a...

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) --  (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting taking place June 21-24, 2025 in New Orleans, Louisiana. Lead authorAbstract TitlePresentation DetailsStephen Graves[212Pb]Pb-VMT-α-NET dos...

 PRESS RELEASE

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in...

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial [212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical dataOn track to submit further clinical updates to scientific congres...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch